Home›Trial›NCT05649748
🔬NCT05649748Phase 2Phase 3ACTIVE NOT RECRUITING

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

Study Summary

The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.

Conditions
Pulmonary Arterial Hypertension
Interventions / Drugs
Treprostinil PalmitilPlacebo
View on ClinicalTrials.gov ↗
Sponsor
INSM
Insmed Incorporated
Rare Disease
F35/100
Study Details
Enrollment91 participants
Primary Completion—
Lead SponsorInsmed Incorporated
Data Retrieved2026-04-11 04:17:39.580872+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.